CBAY

CymaBay Therapeutics, Inc. (CBAY) | Rumor.io

CymaBay Therapeutics

CBAY

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CBAY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 12

CymaBay Therapeutics (CBAY) has seen significant price appreciation, with some shares increasing by over 1700% in a straight line.
The company has been acquired by Gilead Sciences (GILD), and some investors are expressing relief that they didn't sell their shares earlier.
Some users are comparing CBAY's price action to that of other companies, including Agenus (AGEN) and VKTX, suggesting that CBAY may be due for further gains.

Generated by AI

Sentiment

Of the messages about CBAY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +4.55
Bearish	—	—	—	0% -4.55

Bullish· Feb 12

$CBAY's stock has increased significantly, from less than $5 to $32.50, making it a compelling risk-reward opportunity.
The acquisition of $CBAY by Gilead Sciences ($GILD) for $3.6B bodes well for similar companies, such as $VKTX.
$CBAY has provided significant returns to investors, including one user who bought a single share for free and saw it increase in value.

Bearish· Sep 8

The company's stock is overbought and may see further declines after hours and Monday morning.
The company's valuation is unsustainable given its lack of revenue and unlaunched product, with one post highlighting a particularly laughable example of a product worth $1.65B with no profit.
The company's drug has low efficacy and mediocre chances of getting through FDA approval, with one post suggesting an Adcom is likely and could lead to a hard and furious crash if not successful.

Generated by AI

Topics

Of the messages about CBAY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	73.13%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	26.87%

Earnings· Nov 8

CymaBay Therapeutics, Inc. ($CBAY) missed EPS loss estimates by $0.02.
$CBAY is hosting a Q3 2017 earnings call today at 4:30 PM Eastern, available to stream live or on replay.
The call will provide insight into the company's Q3 financial performance and operations.

Analysts· May 12

CymaBay Therapeutics, Inc. (CBAY) has been upgraded to Outperform by multiple analysts, including Evercore ISI, Raymond James, and SVB Leerink LLC, with price targets ranging from $6 to $15.
Analysts Eliana Merle from Cantor Fitzgerald and Derek Archila from Stifel Nicolaus have reiterating their Overweight and Buy ratings, respectively, with price targets of $15 and $6.
The company's stock has seen a significant increase of 144.02% to $4.49, with Cantor Fitzgerald and Evercore ISI setting a price target of $15.

Announcements· Aug 3

CymaBay Therapeutics announced positive topline results from ENHANCE, a Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of primary biliary cholangitis.
Seladelpar demonstrated positive results in the study, which was a placebo-controlled, randomized trial.
The stock price of CymaBay Therapeutics surged after the announcement, increasing by 40.8% in pre-market trading.

Technical Analysis· May 13

$CBAY has cut 1.5R and solid fade 4R after a previous move, indicating potential technical weakness.
The stock is being watched for a head and shoulder pattern, with a potential break below $3 by Friday.
$CBAY has found support above VWAP, with 4.13 being a key level for shorts to break, and the RSI is being used as an indicator in conjunction with volume and VWAP.

Generated by AI

Community

Of the messages about CBAY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	33.18%
Newcomers	—	0%	0%	66.82%

Regulars· Sep 8

BTIG has raised their price target for CBAY to $24, citing an increased probability of success in the treatment of primary biliary cholangitis.
The market is reacting positively to CBAY, with a 12% increase in value and a valuation of $1.7 million, leading some to speculate about an upcoming announcement.
BTIG has also increased the market opportunity for serum alkaline phosphate normalization to 70%, further supporting the potential for CBAY's treatment.

Newcomers· Sep 8

Newcomers are excited about CymaBay Therapeutics' recent price increase, with one user mentioning a 14% gain in a single day.
Several users are focused on the company's potential treatment for liver problems, with one noting that it is one of 400 biotech companies with a treatment in the pipeline.
Analyst Steven Seedhouse has raised his price target for CymaBay Therapeutics to $33, with a potential upside of 119.85%, and a rating of Strong Buy.

Generated by AI

Also Discussed

Investors talking about CBAY also mention

#	Name	Attention
1	GNFT - Genfit S.A.	——
2	MRNS - Marinus Pharmaceuticals, Inc.	——
3	ICPT - Intercept Pharmaceuticals, Inc.	——
4	MRTX - Mirati Therapeutics, Inc.	——
5	BLPH - Bellerophon Therapeutics, Inc.	——
6	Verastem Inc.VSTM	0%0
7	Palvella Therapeutics IncPIRS	0%0
8	JNCE - Jounce Therapeutics, Inc.	——
9	BLCM - Bellicum Pharmaceuticals, Inc.	——
10	Sifco Industries Inc.SIF	0%new